Rokaya El Ansari
University Park
Nottingham, ENG, United Kingdom
Nottingham, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Targeting Glutaminase Isoforms GLS and GLS2 in Luminal Breast Cancer.
Journal: International journal of molecular sciences
Published: December 15, 2025
Tripartite Motif-Containing 2, a Glutamine Metabolism-Associated Protein, Predicts Poor Patient Outcome in Triple-Negative Breast Cancer Treated with Chemotherapy.
Journal: Cancers
Published: January 18, 2024
The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer.
Journal: Cancers
Published: June 09, 2021
SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer.
Journal: Breast cancer research and treatment
Published: October 14, 2020
Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer.
Journal: Cancers
Published: May 20, 2020
PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer.
Journal: BMC cancer
Published: February 24, 2020
The prognostic significance of ALDH1A1 expression in early invasive breast cancer.
Journal: Histopathology
Published: January 24, 2020
The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.
Journal: Breast cancer research and treatment
Published: October 24, 2019
The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.
Journal: British journal of cancer
Published: November 28, 2017
The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
Journal: Breast cancer research : BCR
Published: October 10, 2017
Showing 1-12 of 12
Last Updated: 09/26/2026